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INTRODUCTION
Modafinil is a non-amphetamine type stimulant used in 
narcolepsy, obstructive sleep apnea syndrome and circadian 
rhythm disorder.1 Modafinil has also been tried for disease-
related fatigue, attention-deficit disorder, Alzheimer’s disease, 
age-related memory decline, depression, cognitive impairment 
in schizophrenia, idiopathic hypersomnia, myotonic dystro-
phy, post-anaesthesia grogginess and everyday cat-napping.2 
Even though the action mechanism is not clear, it is thought 
to be distinct from other stimulant drugs.3 Modafinil is known 
to act via its effects on noradrenergic (activation of alpha-1 
receptors)4 and dopaminergic5 neurotransmission. Its wake-
fulness and activity-promoting properties are mostly related 
to its effects on these neuromediators.6
Due to its dopaminergic activity and low abuse potential, 
Modafinil has been used in treatment of cocaine7 and meth-
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amphetamine8 abuse and correction of disturbed cognitive 
functions in alcohol dependent subjects.9 Even though Modafinil 
abuse is not frequent, it’s still possible to encounter patients 
abusing the substance.1 There are rare reports of Modafinil 
abuse in literature. In two of the three case reports that we en-
countered, subjects with Modafinil abuse concurrently had 
history of alcohol and benzodiazepine dependence, whereas 
a case who had schizoaffective disorder did not have history 
of alcohol or drug abuse. Maximum amount of Modafinil in-
take of the cases in these reports was 3,000 mg/day.10-12
In this report, we present a case with high-dose (5,000 mg/
day) Modafinil dependence who had no history of alcohol or 
substance abuse and was diagnosed with attention deficit hy-
peractivity disorder (ADHD).
CASE
Twenty-four years old male, single student, living in coun-
ty town with his parents stated, in his own words that; he had 
been facing difficulty in listening to classes since primary school, 
had issue in concentrating, difficulty in making friends, had 
low academic success, had coerced particularly during tran-
sition to higher education and due to performance anxiety 
had clinical psychologist visits. Developmental and past psy-
chiatric history, corroborated by his parents confirmed these 
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complaints. During childhood he was obviously more active 
than peers, and he was easily distracted by external stimulus. 
The parents reported that, when he was 10 years old, they ad-
mitted to a child psychiatry policlinic complaining of inatten-
tion, difficulty in completing school work, organizing activi-
ties, following instructions, committing frequent mistakes, 
losing belongings and forgetting daily routines. He was diag-
nosed with ADHD by the child psychiatrist and stimulant med-
ication was indicated. However, parents refused medical treat-
ment due to concerns related to side effects. No further treatment 
was searched.
Patient reported that approximately 5 years ago, he begun 
consuming omega 3-6-9 preparations and vitamin supple-
ments in order to increase his social and academic perfor-
mance. Subsequently approximately 3 years ago, without any 
doctor suggestion, he commenced taking Modafinil in 50 
mg/day dose, and gained improvements in attention, self-re-
liance, academic success and social activity. After a while, in 
order to be able to maintain initial effects, he necessitated in-
creasing the dose and went on using Modafinil at 300–400 
mg/day dose during 2 years. It was ascertained that since his 
ailments were not totally resolved and his exam load increased, 
1 year ago he presented to a different psychiatry clinic than 
ours, where 20 mg/day short-acting Methylphenidate was 
initiated for attention deficiency and hyperactivity disorder 
diagnose. It’s realized that, as an addition to Modafinil he 
used short-acting Methylphenidate 60 mg/day. The patient 
stated that, even though he benefited from the Methylpheni-
date treatment, he did not use regularly and discontinued the 
drug. During the last year, he increased the Modafinil dose, 
in order to achieve the initial effects Modafinil and resulted 
in consuming 100 mg tablets, 5 times a day and 10 tablets 
most of the time. Whenever he quit using Modafinil or dimin-
ished the amount, he experienced irritability, anxiousness, 
sweating, tremor and an urge to take excessive Modafinil. 
The case presented to a different psychiatry clinic with a de-
sire to quit Modafinil, where Modafinil was stopped and 
Venlafaxine at 75 mg/day, Risperidone 2 mg/day, Proprano-
lol 80 mg/day and Olanzapine 5 mg/day were initiated. After 
discontinuation of Modafinil, he experienced fatigue, vivid 
and unpleasant dreams, sleeping irregularities, anxiousness, 
and functionality impairment, as previously. Since, despite 
the given treatment his complaints did not subside, he aban-
doned treatment and revert using Modafinil. 
Modafinil that could be purchased over the counter before, 
became a prescription medicine with recent regulations in 
Turkey. Therefore the patient encountered difficulty in access-
ing the drug and presented to our polyclinic. During his an-
amnesis he presented his complaints as necessity to consume 
usurious doses of Modafinil, to be able to achieve the initial 
effects, difficulty in obtaining the medicine, irritability, trem-
or, anxiety, sleep disorder, fatigue, and unpleasant vivid dreams 
when he did not use the drug. It was realized that he was con-
suming 5,000 mg/day Modafinil since 1 month. After evalu-
ation, he was admitted to our psychiatry ward with the initial 
diagnosis of “stimulant use disorder” according to DSM-5 
classification.
During mental state examination performed in our clinic, 
he appeared at his age, was self-sufficient, his associations were 
normal, his speaking rate and amount was partially increased, 
and was anxious. He did not have active psychotic thought 
content, evaluation of actuality was normal. He had irregular 
sleeping pattern, decreased appetite and normal libido.
Family history revealed that his elder brother previously 
had alcohol addiction.
In our psychiatry ward, the patient was introduced Loraz-
epam 2.5 mg/day, Risperidon 1 mg/day and Ketiapin 25 mg/
day. Following abandoning of Modafinil, cravings, pscho-
motor agitation, sweating, tremor, fatigue were observed. 
Therefore his treatment was modified to Diazepam 15 mg/
day, Ketiapin 100 mg/day, Risperidon 2 mg/day. On the third day 
of his admission, the patient was discharged from the ward 
upon his own will. During his first control in outpatient clin-
ic, it was realized that, although he had some benefits from 
treatment, his compliance to medication was poor. He request-
ed prescription of Modafinil, and he did not attend to further 
control visits.
DISCUSSION
Due to weak inhibition of dopamine reuptake pumps, 
Modafinil increases dopamine in some areas of the brain, 
mainly the cortex, striatum and nucleus accumbens.13 Stud-
ies investigating this mechanism revealed that, cortex and 
striatum are diffusely activated following amphetamine ad-
ministration to rats. With Modafinil use, activated areas are 
restricted with paraventricular and suprachiasmatic nuclei, 
anterior hypothalamus, amygdala and tuberomamillary nu-
cleus.14 Modafinil increases the effects of dopamine and nor-
epinephrine by binding to carrier proteins of these catechol-
amines.15 Unlike amphetamine, Modafinil does not have an 
influence on dopamine release and cycle in mouse striatum, 
has very little influence on blood flow to the brain cortex, and 
results in a metabolic activation that is different from amphet-
amine.6 This may be the explanation for its low abuse poten-
tial. Despite all these diversities, Modafinil’s effect related 
with stimulation and behavioral activity are supposed to be 
at least partially involving dopamine.16 D1 and D2 receptors also 
take role in effects of Modafinil on cognitive functions and be-
havior.6
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Affinity of Modafinil to dopamine receptors resembles meth-
ylphenidate. This can be reason of possible risk for abuse.13,17 
Modafinil dependence may be related to its dopamine in-
creasing effect in dopaminergic areas of the brain via reup-
take inhibition.5 Postsynaptic D1 receptors are one of the me-
diators of sensitization; increased dopamine transmission 
results in increased stimulation of D1 receptors, compulsive 
use of Modafinil may be related to this.18-20
Modafinil is thought to enhance cognitive functions such 
as attention, learning and memory via acting differently from 
the typical psychostimulants.5 Promotion of cognitive func-
tions by Modafinil has been investigated in many mental dis-
orders that result in decreased cognitive functions.6 As an ex-
ample, a study with schizophrenic patients using Modafinil, 
in addition to antipsychotic treatment, aiming to decrease cog-
nitive functions had promising results.21 Our case had symp-
toms of ADHD that impaired cognitive functions, such as lack 
of attention, difficulty in concentrating and difficulty in edu-
cational life. Modafinil was helping him to overcome these 
symptoms. There are also studies that presented Modafinil to 
be effective in treatment of ADHD.22,23 Illegal use of Modafinil 
has been reported in substance abusers and patients with or-
ganic mental disease in order to enhance cognitive functions. 
This is also supported with the fact that two of the previously 
reported cases had history of alcohol and benzodiazepine ad-
diction, and the third reported case had schizoaffective dis-
order.24
One report from India mentioned 1,200 mg/day Modafinil 
dose, whereas one report from Turkey mentioned 3,000 mg/
day Modafinil dose.10-12 In the present case, utilization of 
Modafinil at extremely high doses up to 5,000 mg/day may be 
due to a self-medication in order to reinforce its cognitive en-
hancing property and to treat symptoms of ADHD. High dos-
es of Modafinil can cause several side effects like agitation, 
insomnia, tachycardia and elevated blood pressure.25 Our case 
described palpitations, agitation and insomnia after using 
high doses of Modafinil. This was one of the reasons whys for 
seeking treatment. These symptoms were taken into account 
during his treatment planning. There is no controlled study on 
Modafinil dependence; treatment with antidepressants like 
Bupropion and Duloxetine and treatment with benzodiaze-
pines like Clonazepam had been attempted in previously re-
ported cases.10-12
There are 2 case reports in the literature stating that Modafinil 
dependence can occur in patients with previous history of ad-
diction.10,11 ADHD patients are known to be more prone to ad-
diction, however as far as we know, this is the first study dem-
onstrating Modafinil dependence of a case with ADHD. Recent 
suggestion on Modafinil use for ADHD increases the signifi-
cance of the present case report.23
Another important point in this case report is that, to our 
knowledge, there is no report in the literature demonstrating 
Modafinil use as high as 5,000 mg/day. Despite symptoms 
presenting at high dose, the drug did not cause any life threat-
ening condition. 
It has to be kept in mind that Modafinil can cause dependence 
in patients with ADHD. Systematic studies are necessary on 
this field. 
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